ArticleFrontiers in public health2025

Cost-effective analysis of sugemalimab plus chemotherapy as first-line treatment for advanced gastric or gastroesophageal junction adenocarcinoma with PD-L1 CPS ≥5.

Yalan Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.